Skip to content

Individualized dose of remazolam besylate for painless bronchoscopy in elderly patients and its effect on emergence delirium

Individualized dose of remazolam besylate for painless bronchoscopy in elderly patients and its effect on emergence delirium

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117096
Enrollment
Unknown
Registered
2026-01-20
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Remimazolam besylate group:Remimazolam besylate (ED95 from phase I) was used for induction and maintenance.
AI Propofol group(YNMT)· :Patients received induction and maintenance of propofol (body weight standard dose).

Sponsors

Guizhou Aerospace Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.ASA grade I-III; 2.They voluntarily participated and signed informed consent forms.

Exclusion criteria

Exclusion criteria: 1. Allergy to study drugs; 2. Severe liver and kidney dysfunction; 3. Long-term use of sedatives; 4. History of mental illness or cognitive impairment; 5. Emergency surgery.

Design outcomes

Primary

MeasureTime frame
Successful anesthesia (defined as no obvious choking, breathing, body movement and other reactions during glottis insertion);Success rate of anesthesia;The incidence of delirium within 24 hours after the operation;

Secondary

MeasureTime frame
Induction time;Awakening time;The incidence of adverse events such as intraoperative hypotension/respiratory depression;Patient and operator satisfaction;

Countries

China

Contacts

Public ContactChen Yahua

Guizhou Aerospace Hospital

1565423025@qq.com+86 183 1154 4022

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026